La vendita allo scoperto per NeueHealth dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di NeueHealth. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

NeueHealth (NYSE:NEUE) Azioni, Report sulle vendite allo scoperto

NeueHealth

NeueHealth Inc is a value-driven healthcare company grounded in the belief that all health consumers are entitled to high-quality, coordinated healthcare. It consists of two reportable segments: NeueCare - it's a value-driven care delivery business that manages risk in partnership with external payors and serves all populations across The Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act. NeueSolutions - it's a provider enablement business that includes a suite of technology, services, and clinical care solutions that empower providers to thrive in performance-based arrangements.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

CREV

LMNR

NEUE

VENU

I futures statunitensi mostrano leggeri rialzi stamattina, con alcuni titoli chiave da monitorare per possibili movimenti di mercato.

Pre-market: 5 titoli da monitorare oggi, 24 dicembre 2024

NeueHealth Inc

<a href="https://thebearcave.substack.com/p/problems-at-kindercare-learning-companies?utm_source=post-email-title&amp;publication_id=26828&amp;post_id=160491971&amp;utm_campaign=email-post-title&amp;isFreemail=false&amp;r=j3hw3&amp;triedRedirect=true&amp;utm_medium=email" title="https://thebearcave.substack.com/p/problems-at-kindercare-learning-companies?utm_source=post-email-title&amp;publication_id=26828&amp;post_id=160491971&amp;utm_campaign=email-post-title&amp;isFreemail=false&amp;r=j3hw3&amp;triedRedirect=true&amp;utm_medium=email">https://thebearcave.substack.com/p/problems-at-kindercare-learning-companies?utm_source=post-email-title&amp;publication_id=26828&amp;post_id=160491971&amp;utm_campaign=email-post-title&amp;isFreemail=false&amp;r=j3hw3&amp;triedRedirect=true&amp;utm_medium=email</a>

Short Sellers

Watching KinderCare Learning Companies; The Bear Cave Research Issues Report On Co

BMO Capital analyst Michael Zaremski maintains MediaAlpha (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAX#NYSE">MAX</a>) with a Outperform and lowers the price target from $27 to $23.

Price Target

Analyst Ratings

BMO Capital Maintains Outperform on MediaAlpha, Lowers Price Target to $23

NewGenIvf Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) shares are trading higher on Thursday after the company announced it secured $5.2 million in funding in order to drive international expansion, with the potential to secure up to an <a href="https://www.benzinga.com//node/44626169">additional $30.8 million.</a> 
What To Know: The more than $5 million in funding will be used to establish a new fertility clinic in Dubai, which will leverage NewGen&#8217;s recently acquired Microsort technology. The facility will provide services such as IVF with gender selection, egg donation and surrogacy, serving patients from the UAE, the EU and other countries.
The company expects construction of the facility to begin in the&nbsp;second quarter, with its opening targeted for the&nbsp;fourth quarter&nbsp;this year.
&#8220;This strategic funding marks a significant milestone in our global expansion strategy and provides the liquidity we need to drive our long-term growth. The UAE&#8217;s progressive regulatory environment for fertility treatments allows us to offer a full suite of services, making it an ideal region for the next step of our expansion efforts,&#8221; said Sin Wing Fung Alred, CEO of NewGen.
&#8220;By capitalizing on our recently acquired Microsort technology, we plan to establish a strong presence in Dubai, which we hope will serve as a hub to reach patients from a variety of regions. This expansion represents a pivotal step in our commitment to providing world-class fertility solutions to patients around the world.&#8221;
NewGenIvf shares are trading on higher-than-normal session volume at 76.69 million. The average session volume over the past 100 days for the stock is is 1.20 million, per data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
See Also: <a href="https://www.benzinga.com/news/global/25/04/44628368/trumps-tariffs-prompt-china-to-vow-countermeasures-experts-see-retaliation-likely">Trump&#8217;s Tariffs Prompt China To Vow &#8216;Countermeasures&#8217;: Experts See Retaliation Likely</a>
NIVF Price Action: At the time of writing, NewGenIvf shares are trading 29.1% higher at $0.76, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: via Shutterstock

Movers

NIVF

What's Going On With NewGenIvf Shares Thursday?

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/03085740/Cloverw.png" alt="" class="wp-image-9641" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/03085740/Cloverw.png 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/03085740/Cloverw-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/03085740/Cloverw-768x512.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
The Chinese biopharma firm faces a potentially damaging fight over a $224 million upfront payment it received in an ill-fated deal to supply Covid vaccines
<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul>
<li>The Gavi international vaccines alliance has demanded a refund from Clover Bio after scoring a victory in a similar contract disagreement with Novavax</li>
<li>Vaccine delays and strained finances have sent Clover Bio's stock tumbling from an IPO price of HK$13.38 to just HK$0.24</li>
</ul>
China's&nbsp;Clover Biopharmaceuticals Ltd.&nbsp;(2197.HK) was finally looking to the future after a big bet on Covid vaccines failed to pay off. &nbsp;However, decisions made early on in the pandemic are still casting a long shadow.
The company went all-in to produce a Covid vaccine, stalling work on other projects in the race to come up with a domestically produced immunization option. But the Covid crisis had peaked by the time the product was ready for delivery. &nbsp;The investment turned sour and Clover Bio had to lay off nearly half its workforce.
Fast forward to the present day, and the company is now focusing its efforts on vaccines for other respiratory viruses. But the Covid era has presented another belated challenge to its corporate health. An international vaccines alliance served notice last month that it wanted to cancel a supply deal struck with Clover Bio back in 2021 and was seeking a $224 million refund for money already made.
In a&nbsp;<a href="https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0324/2025032400015.pdf">note</a>&nbsp;to shareholders on March 24, Clover Bio said it would vigorously fight the claim from the Gavi vaccines alliance, which it described as being "without merit".
The dispute centers around an advance purchase and option agreement in June 2021 for up to 414 million doses of a Clover Bio Covid vaccine that was then under development. The doses were to be distributed via the World Health Organization's COVAX vaccine-sharing scheme once the product had been cleared for use.
That same year, Clover Bio was hailed as a Chinese vaccine star when it completed a $134 million pre-IPO financing round and went on to list on the Hong Kong Stock Exchange with a market value exceeding HK$15.49 billion ($1.99 billion) on its trading debut. Since then, the stock has tanked to less than 2 percent of its IPO price and company cash reserves have dwindled, leaving Clover Bio financially vulnerable if Gavi succeeds in pressing its claim.
Gavi informed Clover Bio on March 21 of its unilateral intention to terminate the advance purchase agreement. The two sides had initially agreed that Clover Bio would provide a first batch of 64 million doses of its recombinant protein vaccine once the product had been included in the WHO's emergency-use list. Gavi retained the option of buying another 350 million doses to be delivered in 2022.
However, vaccine development dragged out beyond the end of 2021. The two parties revised the agreement in September 2022, extending the cooperation period for four years and deleting the option for the additional 350 million doses. &nbsp;However, by that point Gavi had already made an advance payment of $224 million to cover the materials needed to produce the first batch of 64 million doses.
Gavi insists it is due a refund after only receiving around 12 million doses by the beginning of 2025, far less than the agreed amount. Clover Bio vowed to mount a strong defense, saying the terms of the agreement did not support the Gavi claim.
For accounting purposes, the advance payment in the pre-order agreement differs from the typical upfront payouts in biomedical licensing deals. The money paid to Clover Bio is classed as a contractual liability, while standard licensing agreements count as revenue. The fine print of this deal has not been released, leaving it unclear whether any "force majeure" or other get-out clauses would allow Gavi to recoup its money if the pandemic waned before the vaccines were delivered.
Despite its resolute response, Clover Bio could end up with a big bill to pay, judging from the outcome of a similar case involving the Gavi alliance, which aims to source affordable vaccines for low-income countries.
Vaccine supplier Novavax entered into an advance supply deal for Covid vaccines with Gavi in 2021 for a $700 million advance payment. But in 2022 the company accused the vaccines alliance of violating the deal by failing to buy the agreed number of doses. A settlement was finally reached in April 2024 after multiple rounds of arbitration, with Novavax agreeing repay Gavi up to $475 million in an installment plan.
<h4 class="wp-block-heading">Potential cash crunch</h4>
A similar ruling could have dire consequences for Clover Bio. The vaccine developer's cash reserves and bank balance stood at just 556 million yuan in June 2024, compared with current liabilities of 1.91 billion yuan. The company is still under severe financial strain, despite having brought a Covid vaccine and two quadrivalent flu vaccines to the market.
It reported revenues of 38.41 million yuan in the first half of 2024 and a net loss of 903 million yuan, hit by falling demand for Covid vaccines and a lower-than-expected uptake for flu vaccines, after seasonal outbreaks were less severe than predicted.
As the Covid pandemic took hold, the company had suspended research into cancer and other diseases to concentrate on coming up with a vaccine. However, the Covid vaccine was not approved for sale until China was about to lift pandemic controls. In the end, the huge investment did not deliver the hoped-for payoff. The company announced in 2023 that it would shift its attention to the equally competitive market for quadrivalent flu vaccines, known as AdimFlu-S (QIS).
Market confidence in the brand has collapsed, sending the Clover Bio stock plummeting from a listing price of HK$13.38 in 2021 to just HK$0.24 per share. The company is headed by a family duo, with Peng Liang as chairman and his son Joshua Liang as CEO and executive chairman, each with pay deals well above the industry average. In 2022 the father and son earned 10.45 million yuan and 30.29 million yuan respectively, before the company stopped disclosing executive pay in its financial statements.
The company has recently been working on a business reset, focusing on vaccines for the respiratory virus RSV. It has released positive data from a Phase One clinical trial for its candidate RSV vaccine, but that market is already dominated by giants such as GSK and Pfizer.
It remains to be seen whether Clover Bio can get its RSV vaccine to the marketing stage when its finances are stretched so tight. The one-time vaccine star has slumped to a sector-lagging market value of just HK$300 million, while its RSV-focused rival&nbsp;AIM Vaccine&nbsp;(6660.HK) is worth around HK$5.1 billion.
To keep its dreams alive, the company may need to explore the prospects for a technology licensing deal or an injection of fresh capital.

Asia

Equities

Opinion

Dispute Over Covid Vaccines Casts Doubt On Clover Bio Recovery

While the tariffs announced by President Donald Trump are already dragging markets deep into the red, early signs of strain are beginning to emerge in corporate health indicators, raising concerns that the services sector, the backbone of the U.S. economy, may no longer be <a href="https://www.benzinga.com/news/econ-s">able to sustain growth.</a>
The Institute for Supply Management&#8217;s Purchasing Managers' Index (PMI) survey revealed a marked deterioration in sentiment among service-sector businesses last month, further igniting investor concerns on the state of the economy. 
<h3 class="wp-block-heading">ISM Services PMI Falls More Than Expected</h3>
The ISM Services PMI fell sharply to 50.9% in March, down from 53.5% in February, which had been the highest reading since August 2023. The decline was steeper than expected, with forecasts pointing to a more modest drop to 53%.
This was the lowest reading since December and only marginally above the 50% threshold that separates expansion from contraction.
The Business Activity Index, a gauge of current output, actually strengthened to 55.9% in March from 54.4%, extending its expansion streak to 58 consecutive months. However, forward-looking indicators showed weakness.
The New Orders Index dropped to 50.4% from 52.2%, suggesting waning customer demand, while the Backlog of Orders Index slipped to 45.6%, down from 47.7%, marking a third straight month of contraction.
<h3 class="wp-block-heading">Employment Index Craters, Hiring Freezes Emerge</h3>
The most striking component of the report was the collapse in the Employment Index, which plunged to 46.2% from 53.9%—a 7.7 percentage point drop and a nine-month low, marking its first contraction in six months.
That's a red flag for a services sector that comprises nearly 80% of U.S. private-sector employment. The reading suggests that companies are either slowing down hiring, cutting jobs outright, or scaling back hours amid economic uncertainty.
In the ISM's qualitative commentary, respondents in professional, scientific and technical services reported a loosening labor market. They cited easier hiring conditions, declining staff turnover and a more abundant supply of high-quality job candidates.
One participant said, "Have been able to hire high-quality employees to fill open positions," while another described a "conservative view of the job market and economy," noting they are "not adding head count or resources."
Now, 19.2% of respondents anticipate reducing employment, up from 15% in February.
<h3 class="wp-block-heading">Inflation Still Hot Despite Easing Slightly</h3>
The Prices Index registered at 60.9%, down modestly from 62.6% in February, but still above the 60% mark for a fourth straight month. That signals input cost pressures remain elevated, even as demand cools.
The ISM also noted a surge in mentions of tariff-related cost pressures, citing "a significant increase this month in the number of respondents reporting cost increases due to tariff activity."
<h3 class="wp-block-heading">Market Reactions: Stocks Fall, Traders Eye Four Rate Cuts</h3>
The weaker-than-expected ISM Services PMI intensified the tariff-driven selloff on Wall Street, dragging major U.S. equity indexes to new session lows.
The S&amp;P 500 index – as trakced by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) – fell 4.1% to 5,440 points, eyeing the worst session since September 2022. 
The Nasdaq 100 – tracked by the Invesco QQQ Trust, Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) – sank 4.4%, hitting a 7-month low.
Shares of Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) were down 8.5%, on track for their worst day since March 2020. 
Similarly, major banks like Bank of America Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) and Goldman Sachs Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) fell 8.7% and 9.10%, eyeing their worst days in five years. 
Ralph Lauren (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RL#NYSE">RL</a>) was the S&amp;P 500&#8217;s worst performer for the day, down 17%, also heading for its worst session since March 2020.
In money markets, traders ramped up bets on Federal Reserve rate cuts following the downbeat economic data. According to the CME FedWatch Tool, the probability of four 25-basis-point cuts by December 2025 surged to as high as 67%. 
The shift in expectations triggered a sharp selloff in the U.S. dollar, which plunged 2.1%—its steepest single-day drop since November 2022.
Read now: 
<ul>
<li><a href="https://www.benzinga.com/top-stories/25/04/44627817/retaliation-odds-spike-after-trumps-heavy-tariffs-sending-country-etfs-tumbling">Retaliation Odds Spike After Trump&#8217;s Heavy Tariffs, Sending Country ETFs Tumbling</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Government

Macro Economic Events

Regulations

Broad U.S. Equity ETFs

Econ #s

Economics

ETFs

AAPL

US Services Sector Slows Sharply As Hiring Drops, Tariff Pressures Mount

LiveRamp Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RAMP#NYSE">RAMP</a>) on Thursday announced the expansion of its partnership with Western Union Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WU#NYSE">WU</a>), aiming to enhance the delivery of personalized, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44625345/liveramp-announces-collaboration-with-western-union-media-network-to-unlock-multicultural-audience" rel="noreferrer noopener">omnichannel experiences to multicultural audiences.</a>
This collaboration will connect Western Union&#8217;s Media Network, which boasts a vast and diverse customer base, to LiveRamp&#8217;s data collaboration network, significantly improving advertising capabilities for its partners.
With access to rich customer insights from Deterministic Financial Transaction Information—such as data on senders, receivers, and transaction locations—Western Union is uniquely positioned to offer advertisers targeted, authenticated audience data.
Also Read:<a target="_blank" href="https://www.benzinga.com/25/04/44624245/tariffs-to-plug-the-hole-for-income-tax-cuts-to-come-economists-predict-what-more-could-be-expected" rel="noreferrer noopener"> Trump Tariffs To &#8216;Plug The Hole&#8217; For Income Tax Cuts To Come: Economists Predict What More Could Be Expected</a>
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, WU stock has lost over 24% in the past year. Investors can gain exposure to the stock via WisdomTree U.S. SmallCap Quality Dividend Growth Fund (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGRS#NASDAQ">DGRS</a>),
Through this partnership, marketers can run programmatic campaigns, leverage Western Union&#8217;s first-party data, and use LiveRamp&#8217;s Authenticated Traffic Solution to reach relevant consumers effectively.
The collaboration enables advertisers to run multicultural, omnichannel campaigns with greater accuracy and measure results more effectively. By making Western Union&#8217;s audience data available through LiveRamp&#8217;s extensive collaboration network, brands can unlock valuable insights and drive successful consumer data strategies.
Chris Hammer, Senior Vice President at Western Union, highlighted the importance of this partnership in enhancing targeted marketing and reaching hard-to-reach, multicultural audiences.
Both companies plan to scale their efforts and explore additional data collaboration tools, including data clean rooms, to further fuel innovation in advertising.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, RAMP stock has lost over 26% in the past year. Investors can gain exposure to the stock via&nbsp;Motley Fool Small-Cap Growth ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/TMFS#BATS">TMFS</a>).
Price Action: RAMP shares are trading lower by 5.75% to $25.08 at last check Thursday, while WU shares are down by 2.4%.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44622677/meta-amd-apple-att-among-biggest-us-tech-multinationals-that-may-suffer-the-most-as-tariffs-spark-trade-turmoil-heres-why" target="_blank" rel="noreferrer noopener">Meta, AMD, Apple, AT&amp;T Among Biggest US Tech Giants That &#8216;May Suffer The Most&#8217; As Tariffs Spark Trade Turmoil: Here&#8217;s Why</a></li>
</ul>
Photo via Shutterstock.

General

DGRS

RAMP

TMFS

Western Union And LiveRamp Double Down On Data To Unlock Powerful, Personalized Advertising

Stifel analyst J. Bruce Chan maintains Proficient Auto Logistics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAL#NASDAQ">PAL</a>) with a Buy and raises the price target from $17 to $18.

Stifel Maintains Buy on Proficient Auto Logistics, Raises Price Target to $18

Cantor Fitzgerald analyst Andres Sheppard reiterates Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) with a Overweight and maintains $425 price target.

Reiteration

TSLA

Cantor Fitzgerald Reiterates Overweight on Tesla, Maintains $425 Price Target

Barclays analyst Mathieu Robilliard maintains Millicom Intl Cellular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIGO#NASDAQ">TIGO</a>) with a Equal-Weight and lowers the price target from $310 to $36.

TIGO

Barclays Maintains Equal-Weight on Millicom Intl Cellular, Lowers Price Target to $36

Deep-pocketed investors have adopted a bullish approach towards Wells Fargo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in WFC usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 49 extraordinary options activities for Wells Fargo. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 53% leaning bullish and 36% bearish. Among these notable options, 14 are puts, totaling $1,096,272, and 35 are calls, amounting to $3,525,710.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $57.5 to $85.0 for Wells Fargo over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Wells Fargo's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Wells Fargo's significant trades, within a strike price range of $57.5 to $85.0, over the past month.
<h3>Wells Fargo 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743691577_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>WFC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$2.88</td>
<td>$2.84</td>
<td>$2.84</td>
<td>$72.50</td>
<td>$839.5K</td>
<td>12.7K</td>
<td>9.7K</td>
</tr>
<tr>
<td>WFC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$2.98</td>
<td>$2.94</td>
<td>$2.97</td>
<td>$72.50</td>
<td>$552.4K</td>
<td>12.7K</td>
<td>7.9K</td>
</tr>
<tr>
<td>WFC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$5.3</td>
<td>$5.25</td>
<td>$5.25</td>
<td>$65.00</td>
<td>$328.1K</td>
<td>4.7K</td>
<td>641</td>
</tr>
<tr>
<td>WFC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$6.85</td>
<td>$6.7</td>
<td>$6.73</td>
<td>$70.00</td>
<td>$241.4K</td>
<td>2.0K</td>
<td>370</td>
</tr>
<tr>
<td>WFC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$10.2</td>
<td>$10.1</td>
<td>$10.15</td>
<td>$67.50</td>
<td>$180.6K</td>
<td>196</td>
<td>0</td>
</tr>
</tbody>
</table>

<h3>About Wells Fargo</h3>
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company has four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the US.
<h3>Present Market Standing of Wells Fargo</h3>
<ul>
<li>With a volume of 7,266,595, the price of WFC is down -7.83% at $66.6. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 8 days.</li>
</ul>
<h3>Expert Opinions on Wells Fargo</h3>
Over the past month, 4 industry analysts have shared their insights on this stock, proposing an average target price of $78.62.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Showing optimism, an analyst from RBC Capital upgrades its rating to Outperform with a revised price target of $80. 
&#x2A; An analyst from B of A Securities has decided to maintain their Buy rating on Wells Fargo, which currently sits at a price target of $83. 
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Neutral rating for Wells Fargo, targeting a price of $73. 
&#x2A; An analyst from Citigroup persists with their Neutral rating on Wells Fargo, maintaining a target price of $78. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Wells Fargo, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Wells Fargo's Options: A Look at What the Big Money is Thinking

Stifel analyst Steven Wieczynski maintains Light &amp; Wonder (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNW#NASDAQ">LNW</a>) with a Hold and lowers the price target from $104 to $93.

Stifel Maintains Hold on Light & Wonder, Lowers Price Target to $93

MARA Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>) shares are trading lower amid broader market weakness. The company on Thursday provided a Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) production and <a href="https://www.benzinga.com/pressreleases/25/04/g44625642/mara-announces-bitcoin-production-and-mining-operation-updates-for-march-2025">mining operation update for March</a>.
What Happened: MARA Holdings said it mined 829 bitcoin in March, up 17% month-over-month from 706 bitcoin mined in February. 
Total bitcoin holdings grew to 47,531 as of the end of the month. The company&#8217;s energized hashrate increased 1% to 54.3 EH/s as of March 31. 
&#8220;Energized hashrate grew&nbsp;1%&nbsp;over February and we expect to finish construction of our 40-megawatt data center in Ohio by the end of April. We will continue to focus on being the dominant player in bitcoin mining while expanding our footprint in energy generation,&#8221; said Fred Thiel, chairman and CEO of MARA Holdings.
MARA Holdings shares are seeing some selling pressure Thursday as broader crypto markets fall with global risk assets following sweeping reciprocal tariffs from U.S. President Donald Trump.
The Trump administration announced new <a href="https://www.benzinga.com/markets/25/04/44621408/market-access-has-a-price-trump-unveils-list-of-tariffs-countries-targeted">tariffs</a> on several countries around the world late Wednesday, raising the risk of a global trade war and creating further economic uncertainty.
The S&amp;P 500 was last down nearly 3.5%, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. Bitcoin was down about 4.4% over a 24-hour period, trading around $82,150 at the time of writing. 
MARA Price Action: <a href="http://benzinga.com/quote/mara" target="_blank" rel="noreferrer noopener">MARA Holdings shares</a> were down 9.14% at $11.26 at the time of publication Thursday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Photo: Shutterstock.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

MARA

What's Going On With Bitcoin Mining Stock MARA Holdings Thursday?

Investors with a lot of money to spend have taken a bearish stance on Best Buy Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether this is an institution or just a wealthy individual, we don't know. But when something this big happens with BBY, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 14 options trades for Best Buy Co.
This isn't normal.
The overall sentiment of these big-money traders is split between 28% bullish and 57%, bearish.
Out of all of the options we uncovered, 13 are puts, for a total amount of $799,945, and there was 1 call, for a total amount of $31,850.
<h3>Expected Price Movements</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $50.0 and $75.0 for Best Buy Co, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Best Buy Co stands at 478.4, with a total volume reaching 3,411.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Best Buy Co, situated within the strike price corridor from $50.0 to $75.0, throughout the last 30 days.
<h3>Best Buy Co Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743691572_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BBY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/04/25</td>
<td>$7.0</td>
<td>$6.95</td>
<td>$7.0</td>
<td>$72.00</td>
<td>$121.1K</td>
<td>1.2K</td>
<td>2</td>
</tr>
<tr>
<td>BBY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$3.45</td>
<td>$2.85</td>
<td>$3.4</td>
<td>$50.00</td>
<td>$109.5K</td>
<td>983</td>
<td>323</td>
</tr>
<tr>
<td>BBY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/04/25</td>
<td>$7.9</td>
<td>$7.0</td>
<td>$7.0</td>
<td>$72.00</td>
<td>$86.8K</td>
<td>1.2K</td>
<td>417</td>
</tr>
<tr>
<td>BBY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$0.71</td>
<td>$0.57</td>
<td>$0.69</td>
<td>$55.00</td>
<td>$80.0K</td>
<td>79</td>
<td>1.1K</td>
</tr>
<tr>
<td>BBY</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>04/04/25</td>
<td>$7.95</td>
<td>$5.85</td>
<td>$7.0</td>
<td>$72.00</td>
<td>$70.0K</td>
<td>1.2K</td>
<td>275</td>
</tr>
</tbody>
</table>

<h3>About Best Buy Co</h3>
With $43.5 billion in consolidated 2023 sales, Best Buy is the largest pure-play consumer electronics retailer in the US, boasting roughly 8.3% share of the North American market and north of 33% share of offline sales in the region, per our calculations, CTA, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the covid-19 pandemic, have seen the US e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.
Following our analysis of the options activities associated with Best Buy Co, we pivot to a closer look at the company's own performance.
<h3>Where Is Best Buy Co Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 2,439,428, with BBY's price down by -15.85%, positioned at $63.73.</li>
<li>RSI indicators show the stock to be may be oversold.</li>
<li>Earnings announcement expected in 56 days.</li>
</ul>
<h3>What Analysts Are Saying About Best Buy Co</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $86.8.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Citigroup continues to hold a Buy rating for Best Buy Co, targeting a price of $93. 
&#x2A; Consistent in their evaluation, an analyst from Truist Securities keeps a Hold rating on Best Buy Co with a target price of $81. 
&#x2A; An analyst from Telsey Advisory Group has decided to maintain their Outperform rating on Best Buy Co, which currently sits at a price target of $100. 
&#x2A; An analyst from Morgan Stanley has decided to maintain their Equal-Weight rating on Best Buy Co, which currently sits at a price target of $85. 
&#x2A; Maintaining their stance, an analyst from B of A Securities continues to hold a Underperform rating for Best Buy Co, targeting a price of $75. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Best Buy Co options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Decoding Best Buy Co's Options Activity: What's the Big Picture?

Deep-pocketed investors have adopted a bearish approach towards Carvana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in CVNA usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 37 extraordinary options activities for Carvana. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 27% leaning bullish and 59% bearish. Among these notable options, 28 are puts, totaling $2,966,652, and 9 are calls, amounting to $324,397.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $100.0 to $320.0 for Carvana over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for Carvana options trades today is 1592.22 with a total volume of 8,545.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Carvana's big money trades within a strike price range of $100.0 to $320.0 over the last 30 days.
<h3>Carvana Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743691566_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CVNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/11/25</td>
<td>$18.2</td>
<td>$17.6</td>
<td>$17.9</td>
<td>$215.00</td>
<td>$799.3K</td>
<td>1.1K</td>
<td align="right">719</td>
</tr>
<tr>
<td>CVNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>04/11/25</td>
<td>$9.8</td>
<td>$9.55</td>
<td>$9.69</td>
<td>$200.00</td>
<td>$433.1K</td>
<td>633</td>
<td align="right">719</td>
</tr>
<tr>
<td>CVNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/11/25</td>
<td>$18.0</td>
<td>$17.55</td>
<td>$17.87</td>
<td>$215.00</td>
<td>$235.1K</td>
<td>1.1K</td>
<td align="right">193</td>
</tr>
<tr>
<td>CVNA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$25.25</td>
<td>$23.0</td>
<td>$25.0</td>
<td>$150.00</td>
<td>$197.5K</td>
<td>1.0K</td>
<td align="right">141</td>
</tr>
<tr>
<td>CVNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>04/11/25</td>
<td>$10.0</td>
<td>$9.45</td>
<td>$9.62</td>
<td>$200.00</td>
<td>$127.0K</td>
<td>633</td>
<td align="right">61</td>
</tr>
</tbody>
</table>

<h3>About Carvana</h3>
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage. The foundation of the business is retail vehicle unit sales. This drives the majority of the revenue and allows the company to capture additional revenue streams associated with financing, VSCs, auto insurance and GAP waiver coverage, as well as trade-in vehicles.
<h3>Present Market Standing of Carvana</h3>
<ul>
<li>Currently trading with a volume of 2,359,685, the CVNA's price is down by -15.59%, now at $191.04. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 27 days.</li>
</ul>
<h3>What The Experts Say On Carvana</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $295.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Needham downgraded its action to Buy with a price target of $340. 
&#x2A; An analyst from JP Morgan has decided to maintain their Overweight rating on Carvana, which currently sits at a price target of $365. 
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Overweight rating for Carvana, targeting a price of $325. 
&#x2A; An analyst from Piper Sandler upgraded its action to Overweight with a price target of $225. 
&#x2A; Maintaining their stance, an analyst from B of A Securities continues to hold a Buy rating for Carvana, targeting a price of $220. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Carvana, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

CVNA

Carvana's Options Frenzy: What You Need to Know

Philip Morris Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PM#NYSE">PM</a>) has outperformed the market over the past 5 years by 1.12% on an annualized basis producing an average annual return of 16.54%. Currently, Philip Morris Intl has a market capitalization of $249.35 billion. 
Buying $1000 In PM: If an investor had bought $1000 of PM stock 5 years ago, it would be worth $2,116.77 today based on a price of $160.20 for PM at the time of writing.
<h3>Philip Morris Intl's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743691558_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

Stifel analyst Tom Stephan maintains Bausch &amp; Lomb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLCO#NYSE">BLCO</a>) with a Hold and lowers the price target from $17 to $15.

BLCO

Stifel Maintains Hold on Bausch & Lomb, Lowers Price Target to $15

Stifel analyst Simon Yarmak maintains Alpine Income Property Tr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINE#NYSE">PINE</a>) with a Buy and lowers the price target from $19.5 to $19.25.

PINE

Stifel Maintains Buy on Alpine Income Property Tr, Lowers Price Target to $19.25

Cantor Fitzgerald analyst Andres Sheppard reiterates Lucid Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) with a Neutral and maintains $3 price target.

LCID

Cantor Fitzgerald Reiterates Neutral on Lucid Group, Maintains $3 Price Target

Susquehanna analyst Mehdi Hosseini initiates coverage on SanDisk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDK#NASDAQ">SNDK</a>) with a Positive rating and announces Price Target of $70.

Initiation

SNDK

Susquehanna Initiates Coverage On SanDisk with Positive Rating, Announces Price Target of $70

Cantor Fitzgerald analyst Jonathan Ruykhaver upgrades Zscaler (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) from Neutral to Overweight and raises the price target from $220 to $250.

Comments

NeueHealth

Vendite allo scoperto

NeueHealth (NYSE:NEUE) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO